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Background: Paravalvular regurgitation (PVR) following transcatheter aortic valve
replacement (TAVR) is associated with increased mortality. The purpose of the study
is to evaluate the effect of post-dilatation (PD) on PVR and clinical outcomes.
Methods: Inoperable patients with severe, symptomatic aortic stenosis were
randomized to transfemoral SAPIEN or SAPIEN XT and evaluable 30 day echocar-
diograms (n ¼ 434) were analyzed. PVR and total AR was assessed by an independent
Echocardiography Core Lab as none/trace, mild, moderate and severe according to
American Society of Echocardiography guidelines. The rate of PD was determined for
each enrolling site and grouped by frequency: Group 1: PD performed in < 10% of the
patients in the given site, Group 2: 10% and 25%, Group 3: >25%.
Results: There were signiﬁcant between PD group differences in the incidence of PVR
and total AR (Figure 1A) with the lowest PVR severity in Group 3 (p< 0.05). There was
no difference in 30day mortality or stroke rate between PD groups (Figure 1B).Relevant baseline and outcomes by CKD group
CKD4 (CrCl 30) CKD3 (CrCl 30-60) p-value
Patient Number (N) N¼15 N¼66 -
Baseline CrCl (ml/min),
meanSD
24.44.3 46.39.0 <0.0001
DCrCl (baseline to follow-up)
(ml/min), meanSD
9.613.9 -1.811.2 0.0011
Successful BAV 60% 74.2% -Conclusions: Sites that perform PD on >25% of cases have less moderate and severe
PVR. There is no apparent association between higher rates of PD and early post-
procedural mortality or stroke in this cohort of the PARTNER 2 trial. Further analysis
in a larger patient population should be performed.
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Background: The SAPIEN 3 transcatheter heart valve with the low proﬁle
Commander transfemoral and Certitude transthoracic delivery systems (Edwards
Lifesciences, CA) incorporate features intended to facilitate accurate positioning and
improve paravalvular sealing. We review the initial clinical experience with this
device.
Methods: SAPIEN 3 valves were implanted in 26 patients (age 79.29.3 years,
88.5% male, STS score 6.13.6).
Results: Device size was 26mm in 88.5%, 29mm in 11.5%. Valve positioning was
accurate in all cases, with no moderate or severe paravalvular leaks. Mean aortic valve
gradient decreased from 39.615.7mmHg to 12.44.7mmHg and mean aortic valve
area increased from 0.670.16cm2 to 1.620.35cm2 (p<0.001). Major vascular
complications occurred in 3.8%, major/life-threatening bleeding rate in 7.7%, and
there were no stroke events. Hospital discharge was a median of 3 days after the
procedure. Survival at 30 days was 96.2% with 92.3% of survivors in NYHA func-
tional class I or II.
Conclusions: Early outcomes with the SAPIEN 3 THV were excellent with improved
device positioning and reduced post procedural regurgitation. Longer follow-up of
a larger group of patients is needed to validate these ﬁndings.JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrTCT-788
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Background: Balloon aortic valvuloplasty (BAV) is occasionally a bridge for opti-
mizing transcatheter aortic valve replacement outcomes. This study examined whether
BAV improves renal insufﬁciency in these high-risk patients.
Methods: Our 320 pt BAV database was queried for pts with stage-4 chronic kidney
disease (CKD4, CrCl) <30 ml/min) and stage-3 (CKD3, CrCl 30-59 ml/min). CrCl
was determined using the Cockcroft-Gault equation. Demographics including risk
factors, intraprocedural hemodynamics, pre and post BAV echocardiographic ﬁnd-
ings, periprocedural ﬂuids, medication regimens, and pre and post BAV CrCl (DCrCl)
were compared for differences between the two groups (gp). Successful BAV was
deﬁned as 30% increase in echocardiographic AVA.
Results: 81 pts were identiﬁed, 15 in the CKD4 gp (age 856.2), and 66 in the CKD3
gp (83.77.5). Baseline CrCl in CKD4 was 24.44.3 ml/min, and in CKD3 pts was
46.39.0 ml/min. The mean post BAV improvement in CrCl for the CKD4 pts was
9.613.9 ml/min and CKD3 pts was -1.811.2 ml/min (p¼0.0011) respectively.
There was a signiﬁcant association between age and CrCl improvement across all pts.
The odds ratio of signiﬁcant improvement in CKD4 pts was age dependent up to 82
years of age. The mean follow-up time was 83.97.2 days.
Conclusions: Patients with CKD and aortic stenosis undergoing BAV experience
a modest improvement in CrCl. Improvement was associated with more advanced
CKD and younger age.TCT-789
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Background: Oversizing of balloon-expandable transcatheter heart valves (THVs)
during transcatheter aortic valve replacement (TAVR) is recommended to reduce
paravalvular regurgitation. However excessive oversizing may be associated with
a risk of annular injury.
Methods: Patients (n¼43) who underwent TAVR with an intentionally under-
expanded balloon expandable THV were enrolled in this study. In patients where
the nominal THV cross sectional area exceeded the CT annular area by >20% (or
>15% with adverse root features) the deployment balloon was intentionally
underﬁlled by 5-15%. Study patients were compared to consecutive control
patients, who had nominally ﬁlled THV deployment balloons (n¼87). All patients
underwent pre and post procedural CT imaging as well as transthoracic and
transesophageal echocardiography to assess THV stent geometry, expansion,
eccentricity and hemodynamics.
Results: Among the study group, the THV balloon was underﬁlled by 1, 2, 3, and 4
ml in 7(16.3%), 24(55.8%), 10(23.3%), and 2(4.7%) patients, respectively. On
transthoracic echocardiogram, post procedure THV area was 1.620.38 cm2 in the
study group and 1.660.41 cm2 in the control group(p¼0.602). Mean gradient across
the THV was 11.24.0 mmHg and 10.63.9 mmHg in study and control groups,
respectively (p¼0.411). Paravalvular regurgitation was >mild in 1 patient (3.0%) in
the study group and 6(6.9%) patients in the control group (p¼0.261). Transvalvular
regurgitation was not observed in either group. In-hospital complication rates were
similar. THV expansion at the inﬂow was 85.27.2% versus 102.56.2%(p<0.001),
at the mid-portion 88.17.3% versus 102.46.3% (p<0.001) and at the outﬂow
91.57.2% versus 102.86.0% (p<0.001), in study versus control groups
respectively.
Conclusions: Intentionally underexpanding balloon-expandable THVs as part of
a strategy intended to reduce paravalvular regurgitation and annular injury did not
appear to adversely affect procedural clinical outcomes, THV gradients, or THV areas.
The impact of underexpansion of THVs on durability and late outcomes remains to be
determined.acts/POSTER/Aortic Valve Disease and Treatment B239
